Edgar Xchel Franco-Juárez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Edgar Xchel Franco-Juárez has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Beatriz Silva-Ramírez
Department of Immunogenetics, Northeast Biomedical Research Centre, Mexican Social Security Institute, Monterrey 64320, NL, Mexico
1 shared publication - Ethel Daniela Cabello-Ruiz
Departamento de Química, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, Av. Pedro de Alba s/n, Cd. Universitaria, San Nicolás de los Garza C.P. 66455, Mexico
1 shared publication - Fabiola Castorena-Torres
Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Ave. Morones Prieto 3000, Monterrey, N.L, Mexico
1 shared publication - Katia Peñuelas-Urquides
Departamento de Biología Molecular, Centro de Investigación Biomédica del Noreste, Instituto Mexicano del Seguro Social. Monterrey, 64720, Nuevo León, Mexico
1 shared publication - Luisa Rendón-Garlant
Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolás de los Garza 66451, Nuevo Leon, Mexico
1 shared publication - Mario Bermúdez de León
Departamento de Biología Molecular, Centro de Investigación Biomédica del Noreste, Instituto Mexicano del Seguro Social, Monterrey 64720, Nuevo León, México
1 shared publication
Latest Publications
- Open Access
- 1 February 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (3) , 1760
Mechanistic Insights about Sorafenib-, Valproic Acid- and Metformin-Induced Cell Death in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is among the main causes of death by cancer worldwide, representing about 80–90% of all liver cancers. Treatments available for advanced HCC include atezolizumab, bevacizumab, sorafenib, among others. Atezolizumab and bevacizumab are immunological options recently incorporated into first-line treatments, along with sorafenib, for which great treatment achievements have been reached. However, sorafenib resistance is developed in most patients, and therapeutical combinations targeting cancer hallmark mechanisms and intracellular signaling have been proposed. In this review, we compiled evidence of the mechanisms of cell death caused by sorafenib administered alone or in combination with valproic acid and metformin and discussed them from a molecular perspective.
- 1 February 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (3) , 1760
Open AccessMechanistic Insights about Sorafenib-, Valproic Acid- and Metformin-Induced Cell Death in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is among the main causes of death by cancer worldwide, representing about 80–90% of all liver cancers. Treatments available for advanced HCC include atezolizumab, bevacizumab, sorafenib, among others. Atezolizumab and bevacizumab are immunological options recently incorporated into first-line treatments, along with sorafenib, for which great treatment achievements have been reached. However, sorafenib resistance is developed in most patients, and therapeutical combinations targeting cancer hallmark mechanisms and intracellular signaling have been proposed. In this review, we compiled evidence of the mechanisms of cell death caused by sorafenib administered alone or in combination with valproic acid and metformin and discussed them from a molecular perspective.